At 11 weeks pregnant, 32-year-old Abigail Valletta was diagnosed with triple negative breast cancer.
Valletta underwent a single mastectomy nine days later at the UNC Lineberger Comprehensive Cancer Center. She then started a 12-round chemotherapy treatment. Both procedures were specifically engineered to ensure the safety of Valletta’s baby.
“They always ask, ‘What is your goal?’” Valletta said. “And for when I was pregnant, for the whole team, it was to have a healthy, happy baby.”
Valletta’s cancer was completely removed during her surgery in April 2018. On Saturday, Sept. 29, she gave birth to a baby girl, Madelyn.
This month, the Susan G. Komen foundation awarded the UNC Lineberger Comprehensive Cancer Center $1.125 million for breast cancer research.
“Faculty members who have good ideas or very large projects, which they need funds to complete, they write grants to a number of different organizations,” Shelton Earp, director of the center, said. “With respect to breast cancer, Komen has been a great partner.”
Of the $1.125 million, $400,000 was awarded to Lisa Carey, associate director of clinical sciences. Carey’s research focuses on treatment of a subset of breast cancer that is HER2-positive. HER2-positive tumors contain higher levels of the HER2 protein, which increases the growth of tumors.
“One in five breast cancers have too much HER2, and it makes them aggressive,” Carey said.
Drugs used to target HER2 have significantly improved patients' prognosis. Carey said current treatment includes chemotherapy and use of all five anti-HER2 drugs. Her research will focus on making treatment less harsh for patients when possible.